TY - JOUR
T1 - Hepatitis B virus-associated diffuse large B-cell lymphoma
T2 - Unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin
AU - Deng, Lijuan
AU - Song, Yuqin
AU - Young, Ken H.
AU - Hu, Shimin
AU - Ding, Ning
AU - Song, Weiwei
AU - Li, Xianghong
AU - Shi, Yunfei
AU - Huang, Huiying
AU - Liu, Weiping
AU - Zheng, Wen
AU - Wang, Xiaopei
AU - Xie, Yan
AU - Lin, Ningjing
AU - Tu, Meifeng
AU - Ping, Lingyan
AU - Ying, Zhitao
AU - Zhang, Chen
AU - Sun, Yingli
AU - Zhu, Jun
PY - 2015
Y1 - 2015
N2 - While the epidemiologic association between hepatitis B virus (HBV) infection and diffuse large B-cell lymphoma (DLBCL) is established, little is known more than this epidemiologic evidence. We studied a cohort of 587 patients with DLBCL for HBV infection status, clinicopathologic features, and the immunoglobulin variable region in HBV surface antigen (HBsAg)-positive patients. Eighty-one (81/587, 13.8%) patients were HBsAg-positive. Compared with HBsAg-negative DLBCL, HBsAg-positive DLBCL displayed a younger median onset age (45 vs. 55 years), more frequent involvement of spleen or retroperitoneal lymph node (40.7% vs. 16.0% and 61.7% vs. 31.0% respectively, both p < 0.001), more advanced disease (stage III/IV: 76.5% vs 59.5%, p = 0.003), and significantly worse outcome (2-year overall survival: 47% versus 70%, p < 0.001). In HBsAg-positive DLBCL patients, almost all (45/47, 96%) amino acid sequences of heavy and light chain complementarity determining region 3 exhibited a high homology to antibodies specific for HBsAg, and the majority (45/50, 90%) of IgHV and IgLV genes were mutated. We conclude that 13.8% of DLBCL cases are HBV-associated in HBV-endemic China and show unique clinical features and poor outcomes. Furthermore, our study strongly suggests that HBV-associated DLBCL might arise from HBV antigen-selected B cells.
AB - While the epidemiologic association between hepatitis B virus (HBV) infection and diffuse large B-cell lymphoma (DLBCL) is established, little is known more than this epidemiologic evidence. We studied a cohort of 587 patients with DLBCL for HBV infection status, clinicopathologic features, and the immunoglobulin variable region in HBV surface antigen (HBsAg)-positive patients. Eighty-one (81/587, 13.8%) patients were HBsAg-positive. Compared with HBsAg-negative DLBCL, HBsAg-positive DLBCL displayed a younger median onset age (45 vs. 55 years), more frequent involvement of spleen or retroperitoneal lymph node (40.7% vs. 16.0% and 61.7% vs. 31.0% respectively, both p < 0.001), more advanced disease (stage III/IV: 76.5% vs 59.5%, p = 0.003), and significantly worse outcome (2-year overall survival: 47% versus 70%, p < 0.001). In HBsAg-positive DLBCL patients, almost all (45/47, 96%) amino acid sequences of heavy and light chain complementarity determining region 3 exhibited a high homology to antibodies specific for HBsAg, and the majority (45/50, 90%) of IgHV and IgLV genes were mutated. We conclude that 13.8% of DLBCL cases are HBV-associated in HBV-endemic China and show unique clinical features and poor outcomes. Furthermore, our study strongly suggests that HBV-associated DLBCL might arise from HBV antigen-selected B cells.
KW - B-cell receptor
KW - Complementarity determining region 3
KW - Diffuse large B-cell lymphoma
KW - Hepatitis B surface antigen
KW - Hepatitis B virus
UR - http://www.scopus.com/inward/record.url?scp=84944455696&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84944455696&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.4677
DO - 10.18632/oncotarget.4677
M3 - Article
C2 - 26314957
AN - SCOPUS:84944455696
SN - 1949-2553
VL - 6
SP - 25061
EP - 25075
JO - Oncotarget
JF - Oncotarget
IS - 28
ER -